Merav Kaye

IntuView Ltd. engages in the development of artificial intuition software. Its products include documents exploitation for homeland security, social media monitor, news media monitor, legal support platform, name analyzer, and improvised explosive device recipe detector. The company was founded by Shmuel Bar on May 15, 2005 and is headquartered in Herzliya, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

IntuView Ltd. engages in the development of artificial intuition software. Its products include documents exploitation for homeland security, social media monitor, news media monitor, legal support platform, name analyzer, and improvised explosive device recipe detector. The company was founded by Shmuel Bar on May 15, 2005 and is headquartered in Herzliya, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Xenia Venture Capital Ltd. (Xenia Venture Capital) is a venture capital firm founded in 2003 by Avishay Noam and Anat Tsour-Segal. The firm is headquartered in Tel Aviv, Israel.

Xenia Venture Capital Ltd. (Xenia Venture Capital) is a venture capital firm founded in 2003 by Avishay Noam and Anat Tsour-Segal. The firm is headquartered in Tel Aviv, Israel.

Xenia Venture Capital Ltd. (Xenia Venture Capital) is a venture capital firm founded in 2003 by Avishay Noam and Anat Tsour-Segal. The firm is headquartered in Tel Aviv, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

IntuView Ltd. engages in the development of artificial intuition software. Its products include documents exploitation for homeland security, social media monitor, news media monitor, legal support platform, name analyzer, and improvised explosive device recipe detector. The company was founded by Shmuel Bar on May 15, 2005 and is headquartered in Herzliya, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

IntuView Ltd. engages in the development of artificial intuition software. Its products include documents exploitation for homeland security, social media monitor, news media monitor, legal support platform, name analyzer, and improvised explosive device recipe detector. The company was founded by Shmuel Bar on May 15, 2005 and is headquartered in Herzliya, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Capital Nature Ventures (Capital Nature) is a venture capital subsidiary of Capital Nature Ltd founded in 2012. The firm is headquartered in Tel Aviv, Israel.